Verrica Pharmaceuticals (VRCA) Amortization of Deferred Charges (2020 - 2026)
Verrica Pharmaceuticals (VRCA) posted quarterly Amortization of Deferred Charges of $77000.0 for Q1 2026, down 88.47% year-over-year from $668000.0 in Q1 2025, and up 104.33% quarter-over-quarter from -$1.8 million in Q4 2025.
Verrica Pharmaceuticals (VRCA) Amortization of Deferred Charges (2020 - 2026) Analysis & Trends
Verrica Pharmaceuticals' Amortization of Deferred Charges history runs 7 years deep, the most recent figure standing at $77000.0 for Q1 2026.
- In Q1 2026, Amortization of Deferred Charges fell 88.47% year-over-year to $77000.0; the TTM figure through Mar 2026 stood at -$295000.0 (down 159.84% YoY), while the FY2025 annual figure was $296000.0, down 3.9% from the prior year.
- Amortization of Deferred Charges for Q1 2026 stood at $77000.0, up from -$1.8 million in the prior quarter.
- The five-year high for Amortization of Deferred Charges was $1.9 million in Q3 2025, with the low at -$1.8 million in Q4 2025.
- The 5-year median for Amortization of Deferred Charges is $70000.0 (2022), against an average of $72411.8.
- The sharpest annual moves came in 2024 and 2025: Amortization of Deferred Charges surged 826.76% in 2024, then sank 2969.35% in 2025.
- Verrica Pharmaceuticals' Amortization of Deferred Charges stood at $70000.0 in 2022, then plunged by 174.29% to -$52000.0 in 2023, then jumped by 219.23% to $62000.0 in 2024, then tumbled by 2969.35% to -$1.8 million in 2025, then jumped by 104.33% to $77000.0 in 2026.
- Business Quant data shows VRCA's Amortization of Deferred Charges at $77000.0 in Q1 2026, -$1.8 million in Q4 2025, and $1.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Verrica Pharmaceuticals | 102.80 Mn | 91.60 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 79,000.00 |
| Jun 30, 2026 | 79,000.00 |
| Mar 31, 2026 | 77,000.00 |
| Mar 31, 2026 | 77,000.00 |
| Dec 31, 2025 | -1.78 Mn |
| Dec 31, 2025 | -1.78 Mn |
| Sep 30, 2025 | 1.93 Mn |
| Sep 30, 2025 | 1.93 Mn |
| Jun 30, 2025 | -522,000.00 |
| Jun 30, 2025 | -522,000.00 |
| Mar 31, 2025 | 668,000.00 |
| Mar 31, 2025 | 668,000.00 |
| Dec 31, 2024 | 62,000.00 |
| Dec 31, 2024 | 62,000.00 |
| Sep 30, 2024 | -753,000.00 |
| Sep 30, 2024 | -753,000.00 |
| Jun 30, 2024 | 516,000.00 |
| Jun 30, 2024 | 516,000.00 |
| Mar 31, 2024 | 483,000.00 |
| Mar 31, 2024 | 483,000.00 |